New injection for high blood pressure enters first human safety study
NCT ID NCT06501586
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested a single dose of SGB-3908, an experimental injectable drug, in 40 healthy volunteers and people with mild high blood pressure. The main goal was to check safety and how the body processes the drug. Researchers also looked at changes in a blood protein linked to blood pressure regulation. This is a first step to see if the drug is safe enough for further study.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SGB-3908
What this could lead to
If successful, this could point toward a new injectable treatment for high blood pressure that works by targeting a key protein.
What could go wrong
This is a very early Phase 1 trial with only 40 people, focused on safety. It is too soon to know if it will work for blood pressure control, and side effects are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERTENSION,ESSENTIAL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University Third Hospital
Beijing, Beijing Municipality, 100083, China